Janux Therapeutics, Inc. (NASDAQ:JANX) Director Purchases $53,700,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. purchased 1,200,000 shares of Janux Therapeutics stock in a transaction on Friday, October 18th. The stock was bought at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $53.31 on Friday. The stock has a market capitalization of $2.76 billion, a PE ratio of -43.54 and a beta of 3.54. Janux Therapeutics, Inc. has a 52 week low of $5.65 and a 52 week high of $65.60. The stock has a 50 day moving average price of $46.62 and a two-hundred day moving average price of $45.79.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. The business’s revenue for the quarter was up 709.1% compared to the same quarter last year. Research analysts forecast that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Summit Securities Group LLC bought a new stake in Janux Therapeutics during the 2nd quarter worth approximately $29,000. Amalgamated Bank boosted its position in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares during the last quarter. Plato Investment Management Ltd bought a new stake in Janux Therapeutics during the second quarter worth $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after buying an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Janux Therapeutics in the 2nd quarter valued at $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

JANX has been the topic of several analyst reports. Stifel Nicolaus started coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research note on Monday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Monday, September 16th. UBS Group initiated coverage on shares of Janux Therapeutics in a research report on Thursday. They set a “buy” rating and a $69.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.